Company intelligence / Profile preview

SuperShot

Ann Arbor, Michigan, United States

Ownership: Private
Development stage: Other

Overview

SuperShot Inc. is developing next-generation PRP interventions by concentrating exosomes from platelet-poor plasma and adding them to PRP; preliminary in vitro results show some enhanced stem cell growth, but there is a lack of robust clinical data and regulatory clearance as of October 2025

Therapeutic areas: Rheumatology
Modalities: BiologicPlatelet-rich plasma (PRP) therapyExosome-based therapy
Industry: Biotech

Partnerships

Maintains collaborative ties to Forever Labs

Beyond the preview

Go deeper on SuperShot.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SuperShot.

Explore the full profile